Adverum Biotechnologies Inc. (NASDAQ: ADVM)
$8.55
-0.3700 ( -4.15% ) 1.8M
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Market Data
Open
$8.55
Previous close
$8.92
Volume
1.8M
Market cap
$177.26M
Day range
$6.92 - $11.79
52 week range
$6.38 - $29.70
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 2 | Jun 20, 2024 |
8-k | 8K-related | 13 | Jun 18, 2024 |
8-k | 8K-related | 13 | Jun 11, 2024 |
10-q | Quarterly Reports | 52 | May 09, 2024 |
8-k | 8K-related | 15 | May 09, 2024 |
ars | Annual reports | 1 | May 02, 2024 |
def | Proxies and info statements | 7 | May 02, 2024 |
8-k | 8K-related | 15 | Mar 20, 2024 |
10-k | Annual reports | 86 | Mar 18, 2024 |
8-k | 8K-related | 15 | Mar 18, 2024 |